News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
441,469 Results
Type
Article (25457)
Company Profile (60)
Press Release (415952)
Multimedia
Podcasts (32)
Webinars (7)
Section
Business (122504)
Career Advice (1444)
Deals (25559)
Drug Delivery (84)
Drug Development (64556)
Employer Resources (123)
FDA (11135)
Job Trends (9501)
News (227973)
Policy (24266)
Tag
Academia (1724)
Accelerated approval (4)
Adcomms (20)
Allergies (70)
Alliances (31630)
ALS (79)
Alzheimer's disease (1111)
Antibody-drug conjugate (ADC) (98)
Approvals (11140)
Artificial intelligence (185)
Autoimmune disease (21)
Automation (9)
Bankruptcy (248)
Best Places to Work (8158)
BIOSECURE Act (21)
Biosimilars (69)
Biotechnology (56)
Bladder cancer (70)
Brain cancer (23)
Breast cancer (231)
Cancer (1994)
Cardiovascular disease (140)
Career advice (1216)
Career pathing (16)
CAR-T (119)
Cell therapy (330)
Cervical cancer (17)
Clinical research (53085)
Collaboration (648)
Company closure (1)
Compensation (233)
Complete response letters (20)
COVID-19 (1849)
CRISPR (35)
C-suite (166)
Cystic fibrosis (74)
Data (2057)
Denatured (4)
Depression (36)
Diabetes (221)
Diagnostics (4768)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (30)
Drug discovery (92)
Drug pricing (91)
Drug shortages (22)
Duchenne muscular dystrophy (71)
Earnings (52882)
Editorial (32)
Employer branding (17)
Employer resources (102)
Events (60809)
Executive appointments (489)
FDA (12261)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (532)
Gene editing (93)
Generative AI (15)
Gene therapy (219)
GLP-1 (581)
Government (3581)
Grass and pollen (3)
Guidances (150)
Healthcare (12394)
Huntington's disease (16)
IgA nephropathy (22)
Immunology and inflammation (113)
Indications (25)
Infectious disease (1956)
Inflammatory bowel disease (132)
Inflation Reduction Act (9)
Influenza (40)
Intellectual property (92)
Interviews (253)
IPO (13379)
IRA (48)
Job creations (1690)
Job search strategy (1031)
Kidney cancer (9)
Labor market (29)
Layoffs (284)
Leadership (17)
Legal (5498)
Liver cancer (56)
Lung cancer (292)
Lymphoma (137)
Machine learning (8)
Management (40)
Manufacturing (228)
MASH (70)
Medical device (7980)
Medtech (7983)
Mergers & acquisitions (12727)
Metabolic disorders (586)
Multiple sclerosis (80)
NASH (14)
Neurodegenerative disease (77)
Neuropsychiatric disorders (14)
Neuroscience (1586)
NextGen: Class of 2025 (3746)
Non-profit (2597)
Now hiring (15)
Obesity (304)
Opinion (194)
Ovarian cancer (74)
Pain (81)
Pancreatic cancer (84)
Parkinson's disease (133)
Partnered (16)
Patents (223)
Patient recruitment (96)
Peanut (38)
People (34000)
Pharmaceutical (16)
Pharmacy benefit managers (11)
Phase I (16829)
Phase II (23779)
Phase III (17365)
Pipeline (1236)
Policy (140)
Postmarket research (1588)
Preclinical (7048)
Press Release (32)
Prostate cancer (86)
Psychedelics (25)
Radiopharmaceuticals (190)
Rare diseases (313)
Real estate (2677)
Recruiting (45)
Regulatory (17011)
Reports (37)
Research institute (1632)
Resumes & cover letters (220)
Rett syndrome (4)
RNA editing (4)
RSV (26)
Schizophrenia (66)
Series A (83)
Series B (55)
Service/supplier (3)
Sickle cell disease (42)
Special edition (16)
Spinal muscular atrophy (105)
Sponsored (21)
Startups (1935)
State (1)
Stomach cancer (10)
Supply chain (47)
Tariffs (36)
The Weekly (27)
Vaccines (427)
Venture capitalists (27)
Weight loss (194)
Women's health (19)
Worklife (12)
Date
Today (145)
Last 7 days (799)
Last 30 days (2411)
Last 365 days (25041)
2025 (9142)
2024 (27018)
2023 (30842)
2022 (38417)
2021 (41333)
2020 (38943)
2019 (30909)
2018 (23368)
2017 (22898)
2016 (20471)
2015 (24484)
2014 (17251)
2013 (13016)
2012 (13888)
2011 (14836)
2010 (13412)
Location
Africa (491)
Alabama (46)
Alaska (3)
Arizona (94)
Arkansas (9)
Asia (27079)
Australia (4664)
California (4809)
Canada (1694)
China (445)
Colorado (205)
Connecticut (223)
Delaware (126)
Europe (60105)
Florida (770)
Georgia (152)
Idaho (29)
Illinois (333)
India (20)
Indiana (223)
Iowa (7)
Japan (140)
Kansas (74)
Kentucky (12)
Louisiana (9)
Maine (49)
Maryland (723)
Massachusetts (3329)
Michigan (156)
Minnesota (258)
Mississippi (1)
Missouri (48)
Montana (22)
Nebraska (16)
Nevada (56)
New Hampshire (41)
New Jersey (1408)
New Mexico (17)
New York (1433)
North Carolina (710)
North Dakota (6)
Northern California (2119)
Ohio (115)
Oklahoma (3)
Oregon (24)
Pennsylvania (1009)
Puerto Rico (11)
Rhode Island (18)
South America (714)
South Carolina (18)
Southern California (1870)
Tennessee (73)
Texas (745)
United States (17621)
Utah (137)
Virginia (113)
Washington D.C. (46)
Washington State (448)
West Virginia (2)
Wisconsin (38)
441,469 Results for "act genomics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Government
Congress Re-Introduces EPIC Act to Remove IRA’s ‘Pill Penalty’
While many industry players and observers have high hopes for the EPIC Act, some say budgetary headwinds could make it difficult for the current administration to make meaningful repeals or amendments to the IRA.
February 26, 2025
·
2 min read
·
Tristan Manalac
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and ViiV will push forward with their long-acting antivirals after touting positive early-stage results.
March 12, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Moss Genomics Launches “Perennial” Genomics Platform, Closes on 130 ETH
April 28, 2025
·
7 min read
Government
Trump Nominates Acting Director Monarez as CDC Head
If confirmed, Susan Monarez will have her work cut out for her, facing a measles outbreak that has already killed two people—the first measles-related deaths in the U.S. since 2015.
March 25, 2025
·
2 min read
·
Tristan Manalac
Earnings
WuXi AppTec Remains Resilient Amid Threat from BIOSECURE Act, Continues to Attract New Clients
As the Chinese contract manufacturer awaits the U.S. Senate’s consideration of the BIOSECURE Act, it has added 800 new customers in the first nine months of 2024, while being hit with a 2% revenue decline in the third quarter.
October 29, 2024
·
2 min read
·
Tristan Manalac
Policy
BIOSECURE Act Could Signal a Seismic Shift for Biopharma in US and China
The BIOSECURE Act’s prohibition on doing business with China-based companies may have implications for biotech and biopharma markets on both sides of the Pacific.
July 31, 2024
·
8 min read
·
Sanjukta Mondal
Press Releases
Hearing Device Coverage Clarification Act Reintroduced in House and Senate
Seek to clarify that certain hearing implants are prosthetics and therefore not subject to the hearing aid coverage exclusion, allowing for potential Medicare coverage
March 17, 2025
·
7 min read
Press Releases
Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses
April 22, 2025
·
2 min read
Press Releases
GeneDx Announces Completion of Fabric Genomics Acquisition
May 7, 2025
·
5 min read
Infectious disease
GSK, ViiV Tout 99% Effectiveness for Long-Acting HIV PrEP as Gilead Gains Ground
Real-world evidence show that GSK and ViiV Healthcare’s long-acting pre-exposure prophylaxis Apretude can prevent nearly all HIV infections, while rival Gilead Sciences is moving quickly toward an approval for a twice-yearly option.
October 17, 2024
·
2 min read
·
Tristan Manalac
1 of 44,147
Next
